MVA Smallpox Vaccine
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID), Sanofi Pasteur, a Sanofi Company
Conditions
HIV InfectionsSmallpoxYellow FeverYellow Fever Immunisation
Phase 1
Combination Study With MVA BN and Dryvax
CompletedNCT00082446
Start: 2004-05-31End: 2007-08-31Updated: 2014-12-19
ACAM 3000 MVA at Harvard Medical School
CompletedNCT00133575
Start: 2005-10-31End: 2008-04-30Updated: 2015-01-05
Safety Study of MVA Smallpox Vaccine in HIV-positive Subjects Who Are Vaccinia Naive
TerminatedNCT00282581
Start: 2006-10-31End: 2007-07-31Updated: 2014-01-22
MVA Post-Event: Administration Timing and Boost Study
CompletedNCT00437021
Start: 2007-04-16End: 2009-04-21Updated: 2025-09-19
A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers
CompletedNCT02743455
Start: 2016-07-05End: 2018-03-22Updated: 2026-02-09
Phase 2
Phase 2 Study of Safety, Tolerability, and Immunogenicity of Three Dose Levels of ACAM3000 Smallpox Vaccine
CompletedNCT00466245
Start: 2005-07-31End: 2006-06-30Updated: 2014-01-22
High Dose IMVAMUNE® in Vaccinia-Naive Individuals
CompletedNCT00879762
Start: 2009-05-29End: 2011-03-09Updated: 2025-06-13
Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid IMVAMUNE® (1x10^8 TCID50) Administered Subcutaneously and a Lower Dose Liquid IMVAMUNE® (2x10^7 TCID50) Administered Intradermally
CompletedNCT00914732
Start: 2010-02-28End: 2011-04-30Updated: 2021-02-03
Phase II Trial to Assess Safety and Immunogenicity of IMVAMUNE®
CompletedNCT01827371
Start: 2013-06-30End: 2015-04-30Updated: 2016-09-07